Published April 28, 2026 | Version v1
Preprint Open

BRAF Inhibitor Vemurafenib for BRAF-Mutant Extramammary Paget Disease

Authors/Creators

  • 1. MedicOath

Description

Open Targets identifies BRAF (0.28) as target. KEGG pathways show BRAF involvement in MAPK signaling. BRAF V600E mutations drive oncogenic signaling, and vemurafenib specifically inhibits mutant BRAF kinase activity, successfully used in melanoma.

Notes

IPFS: QmPoLpcnvPAAjzqLVXxEC7moqrGicWxNnnZCskVLTFh645. TX: 0xe15c5ac49b03f9e283b3aa9e2030e3e89844397aad9a6e9c7e1a498495423e14. CC0.

Files

hypothesis.json

Files (366 Bytes)

Name Size Download all
md5:3daff311840280a2d7fabc6e378bf72a
366 Bytes Preview Download